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Abstract 
  BACKGROUND: The role of novel biomarkers like homocystein as a risk factor of coronary 
artery disease (CAD) is being increasingly recognized. Since there is a marked geographical 
variation in plasma homocystein concentration and because of importance of 
hyperhomocysteinemia as a CAD risk factor and due to the paucity of studies in Iran evaluating 
this risk factor in our population, we evaluated the association between plasma total 
homocysteine (tHcy) concentration and CAD risk in Iranian population. 
 METHODS:  In a case-control study, we compared the level of tHcy of forty five patients of 
angiographically proven CAD with forty five subjects without CAD as control group matched for 
age and gender. The patients with diabetes, hypertension, thyroid dysfunction, chronic renal 
failure, hyperlipidemia and obesity and other conventional CAD risk factors were excluded from 
the study. Plasma tHcy was measured using immunoturbidimetry. The results were compared 
between groups using student t test. 
 RESULTS: CAD patients had significantly higher mean plasma tHcy than control group 
(17.1±5.3 versus 14.2±3.8, P= 0.004). 
  CONCLUSION: This study denoted that high plasma homocysteine concentration was 
associated to CAD risk in Iranian people. 
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Introduction 
Coronary artery disease is the leading cause of death 
and disability worldwide. Although Most of coronary 
artery disease patients have at least one of 
cardiovascular risk factors, 20% of patients with 
coronary artery disease have no conventional risk 
factors.1 The role of novel biomarkers including 
homocysteine in atherothrombotic vascular disease 
and prediction of risk of CAD is being increasingly 
recognized.2-6 Many studies found homocysteine level 
to be associated to atherosclerotic disease including 
CAD.7-10 Another investigation showed this risk rises 
with increasing level of plasma homocysteine and has 
no threshold.11 Hyperhomocysteinemia increases the 
risk of coronary artery disease by increased 
thrombosis, adverse effects on endothelial function, 
promoting thickening of the intima and oxidative
  damage of low density lipoprotein.12 The 
hyperhomocysteinemia was reported in 40% of patients 
with vascular disease8 and lowering plasma 
homocysteine level would reduce the risk of CAD by 
16%.13 Additionally, some studies showed 
hyperhomocysteinemia may have prognostic value in 
mortality of patients with CAD.14 The role of elevated 
homocysteine level in CAD seems to be complex and 
further studies are needed to clarify the relationship of 
homocysteine and atherosclerosis. Moreover, some 
studies demonstrated that there is difference in 
prevalence and importance of homocysteine in CAD 
in different ethnic groups.15,16 There are a few studies 
in Iran evaluating the extent of impact of 
hyperhomocysteinemia on CAD risk in our 
population.17,18 The aim of the present study was to 
determine the relationship between 
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hyperhomocysteinemia and CAD in Iranian population. 
Materials and Methods 
The consecutive patients admitted to the Department 
of Angiography of Noor, Sina and Chamran hospitals 
of Esfahan for evaluation of CAD and undergone 
coronary angiography in the year of 2010 were 
included in the study. Based on angiography results, 
the patients were divided into two groups. Those who 
had stenosis of ≥ 75% in at least one of their major 
coronary arteries were considered as CAD or case 
group and other patients served as non-CAD or 
control group. The patients with diabetes, 
hypertension, thyroid dysfunction, chronic renal 
failure, hyperlipidemia and obesity and other CAD 
risk factors were excluded from the study. Forty five 
patients with CAD were compared with forty five 
subjects that had normal coronary arteries in 
angiography, matched for age and gender. The level 
of homocysteine was measured in two groups using 
immunoturbidimetry method. Samples for plasma 
tHcys were placed on ice, serum was separated whitin 
1 hour and was stored at -70˚C. Statistical analyses 
were carried out using SPSS13. Homocysteine and 
continuous variables reported as mean ± SD, were 
compared using student t test. Comparison of 
frequencies was carried out using X2 test or Fishers 
extract test as appropriate. 
Results 
Table 1 shows demographic characteristics of cases 
and controls. Mean age of participants in CAD and 
control groups were 50.8±5.2 and 47.7±8.3 years, 
respectively. CAD group had significantly higher level 
of homocysteine than those in the control group 
(17.1±5.3 versus 14.2±3.8 micromol/lit, respectively, 
P= 0.004). Totally, 16 (35.6%) vs. 4 (8.9%) subjects in 
control and CAD groups, respectively, suffered from 
stable angina. Prevalence of MI and unstable angina 
were significantly higher in CAD group (P = 0.001). 
Homocysteine levels were higher in men than in 
women (16.7± 5.2 and 14.3±3.9 micromol/lit, 
respectively, P=0.019). 
Discussion 
In spite of multiple studies, the role of 
hyperhomocysteinemia as a risk factor of CAD is still 
disputed. Boushey et al.19 estimated that 10% of 
general population CAD risk is attributed to 
homocysteine. They found that a 5-mumol/lit 
increment in tHcy increases odds ratio for CAD as 
great as 1.6 for men and 1.8 for women. Nygard et 
al.14 found a strong association between elevated tHcy 
concentration and overall mortality in CAD patients. 
Consistent graded relationship between plasma tHcy 
concentration and CAD risk were found both in the 
British BUPA cohort and Tromso study.20,21 
  Although almost all retrospective and most of 
prospective studies have confirmed the role of 
homocysteine as an independent risk factor of CAD, 
some studies suggest that hyperhomocysteinemia may 
be secondary to preclinical vascular disease.22,23 
Additionally, several studies demonstrated that 
hyperhomocysteinemia is a causal risk factor for 
CAD.8,24 In other words, elevated level of 
homocysteine interacts with other conventional risk 
factors and in combination with these factors 
increases the risk of atherothrombotic vascular 
disease. A case-control study demonstrated that 
hyperhomocysteinemia had more effect on CAD risk 
in hypertensive patients, smokers and patients with 
hypercholesterolemia than in normal population.8 
Donner et al. excluded the patients with other risk 
profiles from their study and concluded that 
 
Table 1. Demographic and clinical characteristics of study population 
Risk factors  Coronary artery disease 
(CAD)  Controls P  value 
Sex (male/female)    N (%)  30/45 (66.7%)  22/45 (48.9%)  0.09 
Age (years)               (mean ± SD)  50.8±5.2  47.7±8.3  0.06 
tHcy (micromol/lit)  (mean ± SD) 
Men 
Women 
Total 
 
18±5.9 
15.3±3.5 
17.1±5.3 
 
14.9±3.4 
13.6±4.1 
14.2±3.8 
 
0.27 
0.11 
0.004 
Myocardial infarction (mean ± SD)  5 (11.1%)  0 (0%)  0.001 
Stable Angina (mean ± SD)  4 (8.9%)  16 (35.6)  0.001 
Unstable Angina (mean ± SD)  36 (80%)  29 (64.4%)  0.001 
SD; Standard deviation 
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hyperhomocysteinemia is not associated to premature 
CAD in patients without diabetes, hypertension, 
hyperlipidemia.24 A metaanalysis demonstrated 
homocysteine level was less strongly associated to 
ischemic heart disease and stroke in general 
population than has been reported.25 The American 
multiple risk factor intervention trial (MRFIT)26 and 
Finnish North Karelia project27 failed to find any 
association between hyperhomocysteinemia and 
CAD. On the contrary, in Framingham28 heart study a 
strong association between elevated level of 
homocysteine and CAD even after adjustment of 
other coronary risk factors was found. A prospective 
study carried out by Whincup29 had the same result. 
In the present investigation, we excluded subjects 
with other cardiovascular risk factors from our study. 
We found a strong association between plasma tHcy 
and CAD independent of other conventional CAD 
risk factors. 
  Differences in design, statistical approach and 
power may partly explain variations in results of 
different studies but other causes of erratic results 
may be nutritional and large interethnic genetic 
variations. 
  The major determinants of plasma homocysteine 
level are B vitamins and folate intake and genetic 
factors.30-32 Methylene tetrahydrofolate reductase 
(MTHFR) is an enzyme required for conversion of 
homocysteine to methionine. Polymorphism of 
MTHFR in individual with the TT genotype leads to 
reduced enzyme activity and increased homocysteine 
concentration.33 The frequency of polymorphism of 
MTHFR varies in different racial and ethnic groups.34-36 
Investigations showed that almost 12% of Asian 
population is homozygote for T allele (T/T) and up 
to 50% of them are heterozygote for it (C/T).36 
Moreover, studies of Japanese population showed a 
significant association between TT genotype and 
CAD risk.37-39 It is denoted that in addition to 
geographical variation in dietary folate intake, 
geographical variation in the frequency of genetic 
polymorphism may be important in impact of 
hyperhomocysteinemia on CAD risk. There are a few 
studies evaluating relationship between plasma tHcy 
and CAD in Middle East especially in Iran and 
adjustment of other cardiovascular risk factors was 
not carried out by any of these studies. One study 
performed on samples of male adults in the south 
west of Iran found significant association between 
high plasma homocysteine and CAD.17 Kazemi et al. 
study40 showed the patients with abnormal 
angiography reports had higher levels of 
homocysteine compared with the patients with 
normal angiography reports and it was concluded that 
the increased level of homocysteine is an independent 
r i s k  f a c t o r  o f  C A D .  I n  c o n t r a s t ,  i n  N a m a z i  e t  a l .  
study,41 lowering the homocysteine concentration 
with folic acid therapy showed no significant effect on 
in-stent restenosis after PTCA. Our study suggested 
that elevated level of plasma tHcy was associated to 
an increased risk of CAD in Iranian population. A 
great advantage of our study was exclusion of patients 
with other confounding risk factors from our study, 
and then, this relationship seems to be independent 
of other CAD risk factors. 
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